Clinical Data from Phase 1 PK/PD Study of Octreotide for Intranasal Delivery to be Presented at North American Neuroendocrine Tumor Society Symposium

Thursday, October 19, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

SAN DIEGO, Oct. 19, 2017 /PRNewswire/ -- Dauntless Pharmaceuticals, Inc., a privately held biopharmaceutical company focused

on the development of specialty therapeutics, announced today that data from its Phase 1 clinical study of octreotide acetate for intranasal administration (DP1038), will be presented at the annual North American Neuroendocrine Tumor Society (NANETS)
Symposium, October 19-21, in Philadelphia, Pennsylvania.

Dr. Matteo Levisetti, Chief Medical Officer for Dauntless, will present data from the recently-completed Phase 1 clinical study that assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of DP1038, an intranasal formulation of octreotide acetate, in healthy volunteers.  DP1038 demonstrated an excellent safety and pharmacokinetic profile as well as on-target pharmacological effects that support the continued development of the product.

DP1038 leverages patented technology for enhanced intranasal absorption developed by Aegis Therapeutics, LLC, and is being developed as a non-injectable alternative for the treatment of patients with acromegaly and the symptomatic treatment of patients with carcinoid tumors. Specifically, octreotide has been shown to be efficacious in reducing the debilitating diarrhea and flushing episodes associated with metastatic carcinoid tumors.  The somatostatin analog market currently exceeds $2 billion annually with all commercially available formulations requiring subcutaneous or intramuscular injections.

For more information on the DP1038 program or to download a copy of the poster from the NANETS Symposium meeting, please visit www.dauntlessph.com.

About Dauntless Dauntless Pharmaceuticals, Inc. develops specialty therapeutics via a one-asset, one-company model that is structured to facilitate operational efficiencies.  Dauntless 1, its first asset company, was formed to develop DP1038, a therapeutic agent for the treatment of acromegaly and neuroendocrine tumors.  Launched in 2015, Dauntless Pharmaceuticals has raised committed capital of $32 million from Sofinnova and Canaan Partners.

 

View original content:http://www.prnewswire.com/news-releases/clinical-data-from-phase-1-pkpd-study-of-octreotide-for-intranasal-delivery-to-be-presented-at-north-american-neuroendocrine-tumor-society-symposium-300538521.html

SOURCE Dauntless Pharmaceuticals, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store